Oligodendrocyte Progenitor Cell Culture From Human Brain

Demyelinating Diseases Clinical Trial

Official title:

Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00283023
• Other study ID #: RH-CMR-003
• Secondary ID: RVH-CMR-003 gran
• Status: Completed
• Phase: Phase 1
• Start date: December 2007
• Est. completion date: December 2010

Study information

• Verified date: October 2020
• Source: Rajavithi Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Description:

Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female 20-65 years of age

• Informed consent

• Has elective craniotomy surgery

Exclusion Criteria:

• HIV, hepatitis, and other central nervous system (CNS) infections

• Dementia, Alzheimer disease, and neurodegenerative disease

Related Conditions & MeSH terms

• Demyelinating Diseases

Intervention

Procedure:
• Oligodendrocyte progenitor cell culture/craniotomy
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply

Locations

Country	Name	City	State
Thailand	Assistant Professor Subsai Kongsaengdao	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Rajavithi Hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of oligodendrocyte progenitor cell differentiation		one month